Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Dec

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer

Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer

Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML

Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP